The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma

August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, and DLBCL arising from low grade

LOTIS-2 (NCT03589469), an open-label, single-arm trial in 145 adult patients with relapsed or refractory DLBCL or high-grade B-cell lymphoma after at least two prior systemic treatments, was used to support the approval. Patients were given 0.15 mg/kg loncastuximab tesirine-lpyl every three weeks for two cycles, then 0.075 mg/kg every three weeks for the remaining cycles. Patients were treated until their condition progressed or their toxicity became intolerable.

The overall response rate (ORR) was the primary effectiveness outcome measure, as determined by an independent review committee using Lugano 2014 criteria. With a complete response rate of 24.1 percent, the ORR was 48.3 percent (95 percent CI: 39.9, 56.7). (95 percent CI: 17.4, 31.9). The median response time was 10.3 months after a median follow-up of 7.3 months (95 percent CI: 6.9, NE). Sixty-six percent of the 70 patients who received objective responses were censored for response duration before three months.

Thrombocytopenia, increased gamma-glutamyltransferase, neutropenia, anaemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edoema, nausea, and musculoskeletal pain are the most common (20%) adverse reactions in patients receiving loncastuximab tesirine-lpyl, including laboratory abnormalities.

Adverse responses such as edoema and effusions, myelosuppression, infections, and skin reactions are all included in the prescribing material.

The recommended loncastuximab tesirine-lpyl dosage is 0.15 mg/kg every 3 weeks for the first two cycles, then 0.075 mg/kg every 3 weeks for the remaining cycles, given as an intravenous infusion over 30 minutes on the first day of each cycle (every 3 weeks). Dexamethasone 4 mg orally or intravenously twice day for 3 days, starting the day before loncastuximab tesirine-lpyl, should be given to patients.

Reference : https://www.fda.gov/

Check details here.

Take second opinion on lymphoma treatment

Send Details

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025
• Susan Hau

  https://cancerfax.com/author/susan/

  Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
• Susan Hau

  https://cancerfax.com/author/susan/

  Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
• Susan Hau

  https://cancerfax.com/author/susan/

  Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer